Jorde Rolf, Waterloo Knut, Storhaug Hilde, Nyrnes Audhild, Sundsfjord Johan, Jenssen Trond Geir
Institute of Clinical Medicine (R.J., K.W.), University of Tromsø, 9037 Tromsø, Norway.
J Clin Endocrinol Metab. 2006 Jan;91(1):145-53. doi: 10.1210/jc.2005-1775. Epub 2005 Nov 1.
Our objective was to examine the relation between neuropsychological function and subclinical hypothyroidism (SHT), defined as serum TSH of 3.5-10.0 mIU/liter and normal serum free T4 and free T3 levels, and to study the effect of T4 supplementation.
A total of 89 subjects (45 males) with SHT and 154 control subjects (72 males) were recruited from a general health survey (the fifth Tromsø study). Sixty-nine of those with SHT were included in a placebo-controlled, double-blind intervention study with T4 medication for 1 yr.
We used fourteen tests of cognitive function, Beck Depression Inventory, General Health Questionnaire, and a questionnaire on hypothyroid symptoms.
The mean +/- sd serum TSH in the SHT and control group were 5.57 +/- 1.68 and 1.79 +/- 0.69 mIU/liter, respectively. There were no significant differences in cognitive function and hypothyroid symptoms between the two groups, but those with SHT scored significantly better than the controls on the GHQ-30. At the end of the intervention study, serum TSH in the T4 group (n = 36) and the placebo group (n = 33) were 1.52 +/- 1.51 and 5.42 +/- 1.96 mIU/liter, respectively. T4 substitution had no effect on any of the parameters measured.
In subjects with SHT where the serum TSH level is in the 3.5-10.0 mIU/liter range, there is no neuropsychological dysfunction, and compared with healthy controls, there is no difference in symptoms related to hypothyroidism.
我们的目的是研究神经心理功能与亚临床甲状腺功能减退(SHT,定义为血清促甲状腺激素(TSH)为3.5 - 10.0 mIU/升且血清游离T4和游离T3水平正常)之间的关系,并研究补充T4的效果。
从一项普通健康调查(特罗姆瑟第五次研究)中招募了总共89名患有SHT的受试者(45名男性)和154名对照受试者(72名男性)。其中69名患有SHT的受试者被纳入一项为期1年的T4药物安慰剂对照双盲干预研究。
我们使用了14项认知功能测试、贝克抑郁量表、一般健康问卷以及一份关于甲状腺功能减退症状的问卷。
SHT组和对照组的平均±标准差血清TSH分别为5.57±1.68和1.79±0.69 mIU/升。两组在认知功能和甲状腺功能减退症状方面无显著差异,但SHT组在GHQ - 30上的得分显著高于对照组。在干预研究结束时,T4组(n = 36)和安慰剂组(n = 33)的血清TSH分别为1.52±1.51和5.42±1.96 mIU/升。T4替代对所测量的任何参数均无影响。
在血清TSH水平处于3.5 - 10.0 mIU/升范围内的SHT受试者中,不存在神经心理功能障碍,并且与健康对照组相比,甲状腺功能减退相关症状没有差异。